Literature DB >> 18781827

Proprotein convertases as therapeutic targets.

Michel Chrétien1, Nabil G Seidah, Ajoy Basak, Majambu Mbikay.   

Abstract

BACKGROUND: Limited endoproteolysis of precursor proteins is a common mechanism of production of functional proteins and peptides. In the secretory pathway of eukaryotic cells, this endoproteolysis is principally mediated by a family of calcium-dependent serine proteases, generically known as proprotein convertases. Altered expression of these enzymes in experimental animal models and in humans has been associated with numerous pathologies, including infertility, developmental defects, metabolic dysfunctions, cancer, cardiovascular diseases and infectious diseases.
OBJECTIVE: To review experimental evidence of the therapeutic potential of proprotein convertase inhibitors or silencers.
CONCLUSIONS: Several potent inhibitors have been developed and successfully tested. Their therapeutic use must await further improvements in potency, selectivity, cellular delivery and tissue targeting.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18781827     DOI: 10.1517/14728222.12.10.1289

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  13 in total

1.  Highly potent inhibitors of proprotein convertase furin as potential drugs for treatment of infectious diseases.

Authors:  Gero L Becker; Yinghui Lu; Kornelia Hardes; Boris Strehlow; Christine Levesque; Iris Lindberg; Kirsten Sandvig; Udo Bakowsky; Robert Day; Wolfgang Garten; Torsten Steinmetzer
Journal:  J Biol Chem       Date:  2012-04-26       Impact factor: 5.157

2.  On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications.

Authors:  Frédéric Couture; François D'Anjou; Robert Day
Journal:  Biomol Concepts       Date:  2011-10-01

3.  Elongated and Shortened Peptidomimetic Inhibitors of the Proprotein Convertase Furin.

Authors:  Kornelia Hardes; Teodora Ivanova; Bastian Thaa; Gerald M McInerney; Tove Irene Klokk; Kirsten Sandvig; Sebastian Künzel; Iris Lindberg; Torsten Steinmetzer
Journal:  ChemMedChem       Date:  2017-04-04       Impact factor: 3.466

4.  Proteolysis-induced N-terminal ectodomain shedding of the integral membrane glycoprotein CUB domain-containing protein 1 (CDCP1) is accompanied by tyrosine phosphorylation of its C-terminal domain and recruitment of Src and PKCdelta.

Authors:  Yaowu He; Andreas Wortmann; Les J Burke; Janet C Reid; Mark N Adams; Ibtissam Abdul-Jabbar; James P Quigley; Richard Leduc; Daniel Kirchhofer; John D Hooper
Journal:  J Biol Chem       Date:  2010-06-15       Impact factor: 5.157

Review 5.  The biology and therapeutic targeting of the proprotein convertases.

Authors:  Nabil G Seidah; Annik Prat
Journal:  Nat Rev Drug Discov       Date:  2012-05       Impact factor: 84.694

Review 6.  The Role of Proprotein Convertases in Upper Airway Remodeling.

Authors:  Sang-Nam Lee; Joo-Heon Yoon
Journal:  Mol Cells       Date:  2022-06-30       Impact factor: 4.250

7.  Furin targeted drug delivery for treatment of rhabdomyosarcoma in a mouse model.

Authors:  Katarina Hajdin; Valentina D'Alessandro; Felix K Niggli; Beat W Schäfer; Michele Bernasconi
Journal:  PLoS One       Date:  2010-05-03       Impact factor: 3.240

8.  A novel enediynyl peptide inhibitor of furin that blocks processing of proPDGF-A, B and proVEGF-C.

Authors:  Ajoy Basak; Abdel-Majid Khatib; Dayani Mohottalage; Sarmistha Basak; Maria Kolajova; Subhendu Sekhar Bag; Amit Basak
Journal:  PLoS One       Date:  2009-11-26       Impact factor: 3.240

9.  Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations.

Authors:  Janice Mayne; Teik Chye Ooi; Angela Raymond; Marion Cousins; Lise Bernier; Thilina Dewpura; Francine Sirois; Majambu Mbikay; Jean Davignon; Michel Chrétien
Journal:  Lipids Health Dis       Date:  2013-05-10       Impact factor: 3.876

10.  Alterations in gene expression of proprotein convertases in human lung cancer have a limited number of scenarios.

Authors:  Ilya V Demidyuk; Andrey V Shubin; Eugene V Gasanov; Alexander M Kurinov; Vladimir V Demkin; Tatyana V Vinogradova; Marina V Zinovyeva; Alexander V Sass; Irina B Zborovskaya; Sergey V Kostrov
Journal:  PLoS One       Date:  2013-02-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.